我国非小细胞肺癌患者表皮生长因子受体-酪氨酸激酶抑制剂靶向治疗研究进展

Progress of epidermal growth factor receptor-tyrosine kinase inhibitor targeted therapy in Chinese patients with non-small cell lung cancer

细胞表皮生长因子受体(EGFR)突变是引起非小细胞肺癌(NSCLC)发生的原因之一。针对EGFR基因突变靶向药物的出现为NSCLC治疗提供了新方向。一代的吉非替尼及厄洛替尼、二代的阿法替尼、三代的奥希替尼为常见的EGFR靶向药, 在多项大型国际临床试验中显示出良好的疗效。我国NSCLC患者与欧美国家NSCLC患者EGFR基因突变情况有所不同, 文章对我国NSCLC患者的EGFR基因突变特征及针对EGFR突变基因的靶向药物在我国NSCLC患者中的使用现状和进展进行介绍, 旨在探讨我国NSCLC患者中EGFR的突变特征和EGFR-TKI治疗的反应性及预后情况。

Cell epidermal growth factor receptor(EGFR)mutation is one of the causes of non-small cell lung cancer(NSCLC).The emergence of targeted drugs for EGFR gene mutation provides a new direction for NSCLC treatment.The common EGFR-targeted drugs like the first-generation gefitinib and erlotinib,the second-generation afatinib and the third-generation osimertinib have shown their good efficacies in a number of large international clinical trials.EGFR gene mutation in Chinese NSCLC patients is different from that in European and American NSCLC patients.This paper briefly reviews the characteristics of EGFR gene mutation and the current status and progress of EGFR-targeted drugs in Chinese NSCLC patients to investigate the mutation characteristics of EGFR in Chinese NSCLC patients and the response as well as prognosis of Chinese patients to EGFR-TKI therapy.